Clinical trial
A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin
NCT00561353 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- May 31, 2010
- Enrollment
- 121 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.